IMPORTANCE Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with a high incidence of secondary B-cell autoimmunities that limit use. These effects may be avoided through control of B-cell hyperproliferation.
M ultiple sclerosis (MS) is a major, immune-mediated, demyelinating, neurodegenerative disease of the central nervous system and is the leading cause of nontraumatic disability in young adults. The phase 2 trial 1 and pivotal licensing trials 2,3 for alemtuzumab demonstrated that this CD52-depleting monoclonal antibody (mAb) is among the most potent disease-modifying treatments in relapsing MS. [1] [2] [3] [4] This drug can induce long-term remission after only a short course of treatment. 4 However, use of alemtuzumab is limited because it induces a number of secondary B-cell autoimmunities in people with MS. [1] [2] [3] [4] Although these effects may occur rapidly after alemtuzumab infusion, 5 the incidence typically peaks 2 to 3 years after treatment initiation and occurs in about 50% of people with MS within 5 to 7 years of treatment. 4, 6 Although efficacy in people with MS has been attributed to CD4 T-cell deletion and relative sparing of CD4 T regulatory cells, 7-10 less attention has been paid to the reason for the generation of secondary autoimmunities occurring after alemtuzumab administration. Autoimmunity may be attributable to the relative lack of thymic repopulation that occurs after alemtuzumab treatment. 11 However, preferential expansion of memory cells typically occurs after antibodymediated T-cell depletion and is not associated with the development of B-cell autoimmunities.
12,13
We hypothesized that B-cell dynamics are central to secondary autoimmunities and that repopulation kinetics 14, 15 may offer some clues on this aspect. However, the lymphocyte subset repopulation capacities observed in the pivotal phase 3 trials were only partially described 2,3 and have remained unpublished, although based on meeting abstracts, data documenting B-cell issues were collected and analyzed many years ago. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] These data, coupled with recent animal studies using CD52-specific antibodies that indicated lower efficacy of B-cell depletion activity in lymphoid tissues 19, 20 and blockade of immune tolerance induction by CD52-depleting antibody, 20 may shed light on potential adverse effect profiles of alemtuzumab.
Methods
After Freedom of Information requests to the European Medicines Agency in London, England, we received redacted copies of the regulatory submissions of the pivotal phase 3 trials Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I), which focused on drug-naive pwMS, 2 and CARE-MS II, which focused on people with MS who had used beta interferons or glatiramer acetate. 3 Primary data relating to leukocyte numbers were not part of the submission or were not received. The data presented herein only concern the 12-mg/d alemtuzumab dose used in clinical practice that was derived from the tabulated documents supplied. In some instances, the percentages reported ( Figure 1 and Figure 2 )are derived from analysis of the mean data values relating to absolute numbers and may thus have subtle differences from the actual individual percentage data if they had been available. Data used in this study were reported from June 22 to October 12, 2016. Although these trials were recruited following ethical approval of the trials and informed consent, as previously reported, 2,3 no specific ethical approval was obtained or required to view and use these documents in the public domain. The details of participants were anonymous.
Results
The pivotal phase 3 trials 2,3 stated that B cells "recovered 2 / repopulated 3 within 6 months" whereas "T cells recovered 2 / reconstituted more 2 slowly, 2(p1825)3(p1835) approaching the lower limit of normal at 1 year after treatment." The regulatory submission obtained from the European Medicines Agency showed that similar results were obtained after analysis of lymphocyte phenotyping data from the CARE-MS I and II studies ( Table 1) . These results found marked T-cell (Table 1 and Figure 1 ) and B-cell (Table 1 and Figure 2 ) depletion within 1 month after antibody administration and a less marked effect on natural killer cells (CD16 + and CD56 + ), followed by variable degrees of reconstitution of all lymphocyte subsets (Table 1) .
Long-term Depletion of CD4 and CD8 T Regulatory Cells
A rapid (with 1 month) and marked (95.3% in CARE-MS I and II) depletion of peripheral blood CD4 T cells ( Figure 1A ) and depletion of CD8 cells of 85.4% in CARE-MS I and 83.7% in CARE-MS II ( Figure 2B ) were evident. Their numbers remained low and constituted a CD4 T-cell depletion of approximately 69.0% in CARE-MS I and 69.8% in CARE-MS II and a CD8 T-cell depletion of 47.2% in CARE-MS I and 46.4% in CARE-MS II 1 year after alemtuzumab treatment. This depletion was well below the lower reference limit (400/μL [to convert to ×10 9 /L, multiply by 0.001]) 21 for the CD4 + T-cell population, and an average of about 35 months has been reported for CD4 + T-cell repopulation to reach the lower reference limit.
8,21
Although CD4 memory cells may repopulate relatively faster than naive CD4 T cells after depletion, 11,14 naive CD4 (CD45RA + ) ( Figure 1C ) and memory CD4 (CD45RA -) T cells were substantially depleted. The depletion of CD4 T cells may account for the marked effect of alemtuzumab on inhibiting relapsing MS, 7 as occurs in many animal models of MS. 20 In contrast, CD8 T cells may contain pathogenic cells, based on the observation that CD8 T cells predominate in MS lesions.
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Key Points
Question Are lymphocyte subset reconstitution kinetics associated with efficacy and adverse effects of alemtuzumab administration in multiple sclerosis?
Findings Analysis of previously unpublished data from pivotal phase 3 trials in the regulatory submissions of alemtuzumab indicated that efficacy was associated with long-term depletion of memory T and B cells, whereas rapid hyperrepopulation of immature B cells in the relative absence of regulatory CD4 and CD8 T cells create the environment for the generation of secondary B-cell autoimmunity, including anti-drug antibodies.
Meaning Controlling this B-cell hyperrepopulation after alemtuzumab administration may limit the risk for secondary autoimmunity if administration can be performed safely. + , and CD127 low population, which in other studies expresses FoxP3 and other regulatory cell-associated markers and exhibits T regulatory cell function, 9,10 increased from 3.4% to 13.7% in CARE-MS I and from 3.8% to 12.5% in CARE-MS II, 16, 17 supporting the view that T regulatory cell function is enhanced after alemtuzumab administration. However, the reality is that the absolute number of CD4 T regulatory cells remains dramatically reduced by 81% in CARE-MS I and 86.3% in CARE-MS II 10,14 ( Figure 1E ), compared with baseline, consistent with less than 100 T regulatory cells/50 mL of blood reported previously. 14 This loss may be marginal in the context of T-cell control of autoimmunity, because regulatory CD8 cells will repopulate faster than the pathogenic cells driving MS and thus will return in the presence of adequate levels of regulation to limit the reemergence of MS. However, significant loss of T regulatory cells occurs compared with B lymphocytes at a time when B cells are re- populating and hyperrepopulating ( Figure 2 ). This feature may be crucial in the development of secondary autoimmunities.
Creation of a Substrate for B-Cell Autoimmunities by Rapid B-Cell Hyperrepopulation
Although CD19 + B cells reached reference levels within 6 months as reported, 1-3 the substantial hyperpopulation of CD19 + B cells that occurred was ignored (Table 1) . This finding is of interest because the secondary autoimmunities occurring after alemtuzumab treatment in people with MS, such as Goodpasture syndrome, Graves disease, hemolytic anemia, and idiopathic thrombocytopenic purpura, are antibodymediated B-cell autoimmunities. 4 Thus, although B-cell hyperresponsiveness has been reported, 15 this aspect has become largely ignored and was surprisingly not reported in the phase 2 and 3 trial publications or supplementary data. 1-3 CD20-specific antibodies and cladribine deplete B cells, inhibit relapsing MS, and do not induce CD19 B-cell hyperpopulation 23, 24 or secondary autoimmunity. 25, 26 However, autoimmunity sometimes occurs after hematopoietic stem cell therapy without alemtuzumab. 27 This occurrence suggests that marked lymphocyte depletion in people with MS and B-cell recovery in the absence of T-cell regulation may be a key issue in the development of alemtuzumab-induced autoimmunity. The higher frequency of autoimmunities compared with hematopoietic stem cell therapy 4,6,27 may relate to coordination of the T-and B-cell reconstitution kinetics. The most informative aspect to understand the CD19 hyperpopulation (Figure 2A ), which expanded to 35.3% above baseline in CARE-MS I and 26.8% above baseline in CARE-MS II (Table 1) , was the B-cell subset analysis ( Figure 2B-D) . This analysis demonstrated that the CD19 B-cell hyperproliferation ( Figure 2A some people with MS fail to respond adequately to alemtuzumab, even after multiple treatment cycles. 4 In such cases, one should establish whether alemtuzumab neutralization is the cause, and treatment can be switched as persistent neutralizing antibodies become problematic.
Loss of Tolerance After Alemtuzumab Administration
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Although a potential lack of immune tolerance induction may contribute to the generation of alemtuzumab-specific antibodies, this may reflect simple immunogenicity of the molecule. 30 Alemtuzumab may deplete via antibodydependent cellular cytotoxicity with a lesser effect through complement depletion. 19 As such, B-cell depletion is notably limited in the lymphoid tissues, including bone marrow, compared with the peripheral blood in animals 18 and possibly humans. 5, 33 This limitation may allow new autoimmune B-cell responses to be generated. 5 In addition, rapid reactivation of the disease may be allowed, 5,33 if pathogenic cells are sequestered in the bone marrow or lymph glands by previous treatments, such as fingolimod, and not sufficiently depleted owing to the relatively short serum half-life of alemtuzumab.
33
This aspect may also allow drug-specific antibody responses to be generated, and these may develop within the few days required for the first cycle of alemtuzumab to be complete. Once generated, humoral immunologic memory can survive the immune-depleting effects because people with MS treated with alemtuzumab retain their ability to mount an antibody response against common viruses and recall antigens. 34 In the future, reduction of immunogenicity may be feasible with further development of CD52-specific reagents.
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Discussion
A New Mechanism for the Generation of Alemtuzumab-Induced Autoimmunity
The immune system clearly controls relapsing MS, as shown by marked induction of no evident disease activity after hematopoietic stem cell therapy. 27 However, although lymphopenia is a common feature of many immunotherapies, it is not necessarily associated with the development of secondary autoimmunity. Furthermore, the T-and B-cell depletions and reconstitutions by memory T cells and immature B-cell pools that occur after alemtuzumab treatment also occurred after CD4 T-cell 13 and CD20 B-cell depletion 24, 35 treatments that did not cause secondary autoimmunities. We hypothesize the B-cell depletion and rapid repopulation in the absence of effective T-cell regulation in an individual with genetic susceptibility for autoimmunity are key factors in the development of autoimmunity. As such, alemtuzumab induces secondary autoimmunities in people with MS, who may be predisposed to develop other autoimmunities, including thyroid disease, 36 whereas secondary autoimmunities are not a feature among patients receiving alemtuzumab for the treatment of cancer.
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During lymphopenia, some mechanisms that normally serve to maintain host tolerance are temporarily suspended. 38 Peripheral T cells proliferate in response to self-antigens in lymphopenic hosts, but proliferation toward these same antigens is prevented when T-cell numbers are within reference limits. This process, termed homeostatic peripheral expansion, augments peripheral T-cell number and limits repertoire skewing during recovery from lymphopenia and predisposes lymphopenic hosts to autoimmune disease. 38 An association of secondary autoimmunity after alemtuzumab has been suggested with lymphopenia and reduced thymic output, leading to homeostatic T-cell proliferation and chronically activated oligoclonal memory T cells. 15 This finding has prompted the Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (CAM-THY) trial. 39 The development of secondary autoimmunity has also been suggested to be associated with the level of T-cell regulation and interleukin 21 (IL-21) production.
38,40
Investigators 40 have thought that driving cycles of T-cell expansion and apoptosis would increase the stochastic opportunities for T cells to encounter self-antigen. a Data were collected after the administration of 12 mg of alemtuzumab at baseline and 12 months later as reported in the regulatory submission of both the CARE-MS trials.
b Reported as titer of the antibody in the CARE-MS I/CARE-MS II trials.
However, we propose alternative B-cell-centric mechanisms to explain alemtuzumab-induced autoimmunity. Interleukin 21 influences B-cell function, notably regulatory B-cell function, and IL-21 signaling in B cells has been shown to be important in the development of antibody-induced autoimmunity. 41 Furthermore, the lymphocyte repopulation data presented herein suggest that after alemtuzumab administration, a surge of immature B cells repopulates the blood, probably from the bone marrow, 15 in the absence of effective T-cell regulation via CD4 T regulatory cells and CD8 regulatory/ suppressor cells, 20 which could allow escape of autoreactive B cells 41 (Figure 3) . Although suggested to be a potential reason for the generation of autoimmunity, 37 CD4 T regulatory cell depletion has been dismissed as an issue, 14,40 notably when T regulatory cells form a greater population of the regenerating CD4 T-cell pool. 9,10,14 However, the absolute numbers of CD8 T cells and CD4 T regulatory cells are substantially reduced relative to B-cell numbers, at a time when rapid B-cell expansion is occurring and T-cell regulation may be limited, particularly if T regulatory cell function requires cell-cell contact for functional activity to occur. Because T regulatory cells can control the silencing of autoreactive immature B cells exiting the bone marrow as they mature into naive B cells, 42, 43 the conditions are clearly established to allow the escape of B-cell autoimmunity. 38,41 Indeed, deficits related to diminished CD4 T regulatory cell function and increased immature B cells have been related to childhood and adult thyrombocytopenic purpuras, which is one of the adverse autoimmunities after alemtuzumab treatment.
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However, because the autoantibody production is likely to be CD4 T-cell dependent, autoimmunity will require T-cell help, and thus autoimmunity is unlikely to occur until CD4 T-cell numbers regenerate (Figure 3) . This situation creates a delay between the time of B-cell hyperreactivity and the development of autoimmunity. This finding is consistent with the observation that autoimmunity peaks in the years 2 to 3 as CD4 T cells repopulate, with approximately 20% of people with MS developing thyroiditis compared with approximately 10% in years 2, 4, and 5 in the CARE-MS follow-up studies. 6 and these subsets may harbor the pathogenic cells that control MS. Although most experts in the field believe T cells drive disease activity in people with MS, CD4 T-cell depletion is perceived to have failed to control MS after CD4 mAb-induced depletion. 12 However, the 70% CD4 depletion targeted to maintain cell numbers greater than 250/μL in CD4-specific mAb trials 12 was substantially less than the 95% CD4 T-cell depletion achieved with alemtuzumab, which provided a clear suppression of disease activity. 2,3 Because some effects were seen on magnetic resonance imaging lesion loads after treatment with CD4 mAb administration after depletion of approximately 70% of CD4 T cells was achieved, 12 this may be the minimum depletion required for disease inhibition. However, evaluating the association of cell numbers with disease activity after alemtuzumab treatment has not always proved to be informative 7, 8 and this is likely to remain an issue. Until the frequency of antigen-specific pathogenic cells relative to the disease activity can be reliably monitored, gauging the lymphocyte level required to control disease will not be possible.
However, that persistent T-cell depletion sustained for over 2 years, as shown after alemtuzumab treatment, coupled with tolerization of pathogenic cells by the repopulating regulatory systems that regenerate at a faster rate than pathogenic cells, may underscore why repeated treatment is often not required and long-term remission is induced 4 (Figure 3 ).
Although T cells are considered to drive disease in MS, most agents that inhibit relapsing MS target B cells. That levels of CD19 + and CD27 + cells remain low after alemtuzumab treatment suggests that this subset of B cells may be a key substrate of the mechanism by which alemtuzumab controls the disease. Similarly, CD19 + and CD27 + cells are targeted by CD20-specific mAb, 24, 35 and this approach appears to offer comparable benefit, at least on some outcomes. 2,26 Although B-cell depletion has been argued to block antigen-presenting capacity to stimulate pathogenic T cells or make pathogenic antibodies, an alternative view could be that these therapeutic antibodies are actually deleting the B-cell reservoir of infectious agents, such as Epstein Barr virus, and possibly endogenous retroviruses that have consistently been implicated as etiologic factors in MS and other autoimmune diseases.
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Limitations
Events occurring within the central nervous system or lymphoid tissues are not captured by analysis of the blood and may be key to understanding the pathogenesis. Importantly, the unavailability of the primary data makes it impossible to properly interrogate the results, notably to determine the significance, if any, of cell subset levels and neutralizing antibodies on safety and disease activity at the level of individuals.
Conclusions
We hypothesize that limiting B-cell reconstitution until T regulatory and suppressor cell function returns may limit B-cell autoimmunities after alemtuzumab treatment of people with MS. However, adding other B-cell-targeting therapy after alemtuzumab treatment may increase the risk for serious infections and cancers, thereby leading to worse outcomes compared with the development of B-cell autoimmune diseases, which are often manageable and nonfatal. Therefore, careful consideration is needed before such an approach is undertaken and should be formally tested to ensure patient safety. 
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